During our molecular docking experiments, we also discovered that quercetin exhibits a strong affinity for COL1A1 (≤-5 kcal/mol), suggesting that the active components of SLFM can potentially treat or alleviate AF through this target. This evidence concerns the gene COL1A1 and atrial fibrillation.